LunGuard

Reflux Prevention Device for Ventilated and Tube-fed Patients

Health Tech & Life Sciences
Non Active, Dec 2020 ceased to operate
Seed Yavne, Israel Founded 2009
LinkedIn
Last updated 2026-06-18
Total raised
$600K
Last: 2009-01
Stage
Seed
Founded
2009
Headcount
1-10
HQ
Yavne, Israel
Sector
Health Tech & Life Sciences

About

LunGuard is developing a proprietary physiological integrated patient interface system for ICU ventilated and fed patients. Its technology pipeline is built around the Reflux Prevention System (RPS technology). The system incorporates six active safety and efficient features: an intelligent reflux prevention system to safely reduce VAP; it enables more aggressive ventilation and nutrition therapy; a smart system for ETT cuff sealing monitoring and control to reduce aspiration; it enhances patient safety by the integrated pulmonary pressure detector and enables more effective ventilation of obese and asthma patients; the Smart Tube which incorporates PH sensors that serve as a reflux episode indicator; and a Vomiting indicator based on pressure technique. The system can be used with any ventilator or feeding system and replaces the NG tube with its own proprietary smart sensor. The Reflux Prevention feature is capable of managing reflux, reducing pulmonary aspiration and significantly lowering the occurrence of Ventilator Associated Pneumonia (VAP) in ventilated patients.

Funding history · 1 round · $600K total

Q&A

What is LunGuard's primary focus?
LunGuard is developing a proprietary physiological integrated patient interface system designed for ICU ventilated and tube-fed patients, with a focus on reflux prevention.
When was LunGuard founded?
LunGuard was founded in January 2009.
What is the current status of LunGuard?
LunGuard is currently inactive, having ceased operations in December 2020.
How much funding has LunGuard raised in total?
LunGuard has raised a total of $600,000 USD.
Which investors participated in LunGuard's funding round?
In January 2009, LunGuard received funding from investors including Maayan Ventures.
What is LunGuard's employee count range?
LunGuard operates with 1-10 employees.
What is the core technology behind LunGuard's system?
LunGuard's technology pipeline is built around its Reflux Prevention System (RPS technology), which aims to reduce Ventilator Associated Pneumonia (VAP).
Does LunGuard hold any patents?
Yes, LunGuard holds one patent.

Team · 1

Founder · Co-founder (No longer with the company)
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Sensing
Target customers
ConsumersDemographics & FamilyBabiesHealthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

preventionmedical-devicesrespiratoryhospitalsventilationfeedingsensorspulmonary
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)